Stoke Therapeutics' (STOK) Buy Rating Reaffirmed at HC Wainwright

Stoke Therapeutics (NASDAQ:STOK - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a note issued to investors on Tuesday, Benzinga reports. They currently have a $35.00 price target on the stock. HC Wainwright's price objective would indicate a potential upside of 193.13% from the stock's previous close.

Several other research analysts have also recently commented on STOK. TD Cowen upgraded shares of Stoke Therapeutics from a "market perform" rating to an "outperform" rating in a report on Tuesday, March 26th. Wedbush boosted their price objective on shares of Stoke Therapeutics from $13.00 to $17.00 and gave the company an "outperform" rating in a research report on Tuesday, March 26th. JPMorgan Chase & Co. increased their target price on shares of Stoke Therapeutics from $6.00 to $13.00 and gave the stock a "neutral" rating in a research report on Tuesday, March 26th. Needham & Company LLC reissued a "buy" rating and set a $22.00 target price on shares of Stoke Therapeutics in a research note on Monday. Finally, Canaccord Genuity Group upped their price target on shares of Stoke Therapeutics from $18.00 to $21.00 and gave the stock a "buy" rating in a research note on Tuesday, March 26th. One equities research analyst has rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $20.57.

Stoke Therapeutics Stock Up 0.6 %

Stoke Therapeutics stock traded up $0.07 during trading hours on Tuesday, hitting $11.94. 738,061 shares of the company traded hands, compared to its average volume of 957,996. Stoke Therapeutics has a 1-year low of $3.35 and a 1-year high of $16.40. The firm's 50-day simple moving average is $10.23 and its two-hundred day simple moving average is $6.68. The firm has a market cap of $622.31 million, a P/E ratio of -5.04 and a beta of 0.82.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its earnings results on Monday, March 25th. The company reported ($0.60) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.02. The firm had revenue of $2.80 million during the quarter, compared to analyst estimates of $3.70 million. On average, equities research analysts predict that Stoke Therapeutics will post -2.28 earnings per share for the current year.

Insider Transactions at Stoke Therapeutics

In related news, CFO Stephen J. Tulipano sold 4,116 shares of the business's stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total value of $25,107.60. Following the completion of the sale, the chief financial officer now directly owns 20,746 shares in the company, valued at approximately $126,550.60. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other news, CFO Stephen J. Tulipano sold 4,116 shares of the company's stock in a transaction that occurred on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $25,107.60. Following the completion of the transaction, the chief financial officer now directly owns 20,746 shares in the company, valued at $126,550.60. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Edward M. Md Kaye sold 11,150 shares of the business's stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $6.10, for a total transaction of $68,015.00. Following the transaction, the chief executive officer now directly owns 69,350 shares in the company, valued at approximately $423,035. The disclosure for this sale can be found here. In the last quarter, insiders sold 3,622,741 shares of company stock worth $41,935,115. 11.30% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Bank of New York Mellon Corp grew its position in Stoke Therapeutics by 2.8% in the third quarter. Bank of New York Mellon Corp now owns 107,254 shares of the company's stock valued at $423,000 after acquiring an additional 2,926 shares during the period. BNP Paribas Financial Markets boosted its position in Stoke Therapeutics by 86.2% in the first quarter. BNP Paribas Financial Markets now owns 14,330 shares of the company's stock valued at $193,000 after buying an additional 6,636 shares in the last quarter. Dorsey & Whitney Trust CO LLC bought a new stake in Stoke Therapeutics during the third quarter worth about $43,000. Sherbrooke Park Advisers LLC bought a new stake in Stoke Therapeutics during the third quarter worth about $48,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Stoke Therapeutics by 9.3% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 146,076 shares of the company's stock worth $576,000 after buying an additional 12,478 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.